April 2018

Discern successfully submitted an abstract titled “Measuring the Quality of Personalized Medicine: A Review of the Current Approach and Vision for the Future” to the National Comprehensive Cancer Network (NCCN) as part of our work with the Pharmaceutical Research and Manufacturers of America (PhRMA) on quality measurement for personalized medicine. In March, Discern Director Russ Montgomery and Project Manager Kaitlyn Whiton attended and presented a poster of the work at the 2018 NCCN Annual Conference in Orlando, Fl.

The abstract and poster reviewed existing oncology quality measures to identify specific challenges in the current measures and to recommend new approaches. Among our recommendations was the need for prioritizing and developing cross-cutting, patient-centered oncology measures that are applicable across cancer types.

View the NCCN Poster